Dr Claudio Cerchione speaks to ecancer about carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma. Initially, he talks about the background of the study.

Dr Cerchione then explains the methodology and results of the study. He concludes by discussing the impact of the results from this study can have on the future treatment of multiple myeloma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.